C

Cronos Group

Cultivates, manufactures, and markets cannabis products

Field Sales Representative

Full-TimeUpdated on 10/21/2026
No salary listed
Mid
Israel
In PersonFrequent travel throughout Israel is required.
Sales & Account ManagementField Sales

About the job

Requirements
  • Minimum three years of experience in field sales or a similar commercial role.
  • Experience working with pharmacies; experience in the pharmaceutical, medical cannabis, or paramedical sectors is a significant advantage.
  • Strong sales, negotiation, and deal-closing capabilities.
  • Sales-oriented and analytical, with the ability to monitor performance and act on commercial insights.
  • Good understanding of digital tools and sales reporting systems.
  • Ability to work independently, manage priorities, and use time effectively.
  • A valid driver’s license is mandatory.
  • Willingness and ability to travel frequently throughout Israel.
  • Professional presence and self-confidence.
  • Excellent interpersonal communication and the ability to build trust with customers.
  • Strong service orientation and relationship-management skills.
  • High motivation and resilience in achieving challenging targets.
  • Initiative and creativity in developing business relationships and sales opportunities.
  • Problem-solving, collaboration, adaptability, and flexibility.
Responsibilities
  • Present the company and its products to pharmacy teams, prospective customers, and relevant stakeholders.
  • Provide ongoing personal support, professional guidance, and product training to pharmacy teams.
  • Initiate and promote sales of the company’s products, identify new opportunities, and convert them into business growth.
  • Manage orders and support inventory management at pharmacies to maintain appropriate product availability.
  • Develop and manage the existing customer portfolio while expanding the customer base and strengthening account penetration.
  • Initiate and conduct sales meetings with pharmacies, with a primary focus on Super-Pharm branches.
  • Lead commercial negotiations and reach mutually beneficial agreements in line with company policy.
  • Build and maintain strong, long-term customer relationships; address concerns and provide effective solutions.
  • Meet or exceed monthly and quarterly sales and revenue targets.
  • Monitor sales key performance indicators and provide accurate, detailed, and timely reports to the Sales Manager.
  • Report on field activity, customer feedback, market trends, competitor activity, and emerging commercial opportunities.
  • Collaborate closely with the company’s Marketing, Customer Service, and Operations teams.
  • Conduct sales and product training, including sales techniques and key product attributes, when required.

About the company

C

Cronos Group

View
Website

Cronos Group is a Canadian cultivator, manufacturer, and marketer of cannabis and cannabinoid products for adult-use and medical customers, with operations in Canada and growing international reach. Its product lineup includes branded cannabis items such as Spinach and PEACE NATURALS, along with flower, vapes, edibles, and other formats sold through recreational and medical channels. The company operates the Cronos GrowCo cultivation facility in Kingsville, Ontario, and pursues growth through branded products and geographic expansion. A key differentiator is its strategic partnership with Altria, which owns about 45% of Cronos following a $2.4 billion investment in 2018, supporting product development, distribution, and capital strength. Cronos aims to broaden its footprint by entering Europe, notably through the planned acquisition of CanAdelaar, the Netherlands’ largest adult-use cannabis company, to establish a presence in the Dutch and broader European market.

Company Size

201-500

Company Stage

IPO

Headquarters

Toronto, Canada

Founded

2013

Get referred to Cronos Group

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 58% to $53 million, with record gross profit.
  • Spinach held Canada's top edibles share and led vapes again in Q2 2026.
  • Cronos ended Q2 2026 with $827 million cash, no debt, and six EBITDA-positive quarters.

What critics are saying

  • Israel opened a new August 2026 dumping probe on Canadian medical cannabis imports.
  • CanAdelaar's Dutch closing still waits for regulatory clearance, delaying European expansion.
  • A sustained Israel duty regime would crush a major export lane and derail profitability.

What makes Cronos Group unique

  • Cronos GrowCo in Kingsville is purpose-built cannabis greenhouse capacity with Mucci Farms.
  • Cronos runs a hero-brands portfolio: Spinach, Peace Naturals, Lord Jones, and LIT.
  • Tissue culture and genetics screening produced 150,000 seeds and 20,000 annual plantlets.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Performance Bonus

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Oct 13th, 2026
Cronos, Omai Gold and McChip: three Canadian penny stocks with solid balance sheets

Simply Wall St has highlighted three Canadian penny stocks with relatively strong finances, as the International Monetary Fund warns that global government borrowing costs could spike on debt and inflation pressures. Cronos Group (TSX:CRON), a cannabis producer, has a market cap of CA$1.70 billion. It earns about $179 million from cannabis products, mostly in Canada, then Israel and other markets. Omai Gold Mines (TSXV:OMG) is a Toronto-based junior miner focused on one gold project in Guyana. Its market cap is CA$1.50 billion, though it faces funding pressure and is unprofitable. McChip Resources, a Toronto-based investor in oil, gas, and Saskatchewan potash, has a market cap of CA$4.4 million. Its earnings grew 80.9% last year, and its price-to-earnings ratio is about 1.8, but it has reported recent quarterly losses.

BBNS
Sep 25th, 2026
Cronos Group Investor Day highlights cannabis growth, cash flow and global ambitions.

Cronos Group Investor Day highlights cannabis growth, cash flow and global ambitions. Posted by Andrew Walz on Sep 25th, 2026 Cronos Group (NASDAQ:CRON) used its first Investor Day to outline its cultivation, genetics, brand and financial strategy, emphasizing its purpose-built greenhouse partnership with Mucci Farms, continued international expansion and a focus on cash flow generation. Chief Executive Officer Mike Gorenstein said Cronos was established with the goal of building a global cannabis platform that could develop intellectual property and enter additional markets as regulations evolved. He said the company's strategy has centered on partnering with specialists rather than seeking to manage every part of the value chain internally. That approach is reflected in Cronos GrowCo in Kingsville, Ontario, its cultivation partnership with Mucci Farms. Bert Mucci, CEO of Mucci Farms, said the company operates 800 acres of controlled-environment agriculture, employs about 3,500 people and sells roughly 65% to 70% of its production into the United States. Purpose-Built cultivation and expansion capacity. Mucci said GrowCo was designed specifically for cannabis rather than converted from a vegetable greenhouse. The facility includes dehumidification, chilling systems, concrete flooring and a triple-screen setup designed to manage energy use and help control pests and humidity. He said labor, electricity and natural gas are the largest cultivation costs. Gorenstein said greenhouse cultivation provides advantages in predictability, year-round production, energy efficiency and scalability. He added that outdoor cultivation can be attractive for extracts and inputs, while indoor cultivation may retain a role in craft-oriented segments. GrowCo's second phase is fully planted and utilized, according to Gorenstein, although the company expects to continue identifying gains from automation, genetics and operating efficiencies. He said Cronos has not announced a further expansion. Mucci said that, based on the experience gained from the first two phases, a comparable facility could potentially be built in about 12 months. On potential U.S. opportunities, Gorenstein and Mucci said they would favor purpose-built facilities over retrofits. They cited climate, humidity, energy costs, water access, labor and state regulations as key considerations. Mucci noted that colder climates can offer a seasonal "clean start" by reducing pest pressure. Genetics, tissue culture and product quality. Lasse Schulze, Cronos' senior director of flower product development and agronomics, said the company's genetics program was established in 2018 and employs about 16 people across laboratories in Canada and other countries. The program focuses on yield, THC potency, aroma, flower size and disease resistance. Schulze said Cronos has produced more than 150,000 seeds, screened more than 6,000 genotypes and developed capacity to produce more than 20,000 tissue-culture plantlets annually. Less than 1% of tested genetics ultimately reach the market, he said. The company uses tissue culture to propagate plants in sterile environments, a process Schulze said removes diseases, viruses, viroids and other biological burdens that can accumulate through conventional cutting-based propagation. Cronos also tests genetics across seasons and environmental conditions before commercializing them, with the process typically requiring at least one to two years. Gorenstein said the foundational breeding work can extend the effective development timeline to about four years. Schulze said Cronos has increased yield per plant and cannabinoid content over time. He also said the company's Wedding Cake and GMO genetics have ranked first and second in Israel, respectively, while international flower revenue excluding Israel increased to $15 million in the first half of 2026 from $1 million in the first half of 2024. Chief Growth Officer Jeff Jacobson said Cronos uses a "hero brands" strategy rather than launching a broad collection of overlapping brands. Its portfolio includes Spinach in Canada's adult-use market, Lord Jones for more premium offerings, Peace Naturals for medical markets and LIT for more affordable flower products in markets including Israel, Germany and the United Kingdom. Jacobson said Spinach is the No. 2 cannabis brand by retail share in Canada and holds leading positions in several product categories. He said the company has focused its innovation efforts on edibles, vapes and, more recently, pre-rolls. * SOURZ by Spinach has held the No. 1 position in Canadian edibles for eight consecutive quarters and has more than 20% market share, according to Jacobson. * Spinach PUFFERZ, the company's disposable vape offering, has generated more than CAD 20 million in retail sales and holds more than 10% of the disposables category, he said. * Flower remains foundational to Cronos, with Jacobson saying its ranking has recovered to approximately No. 3 or No. 4 after prior supply constraints. Financial position and risks. During the financial portion of the event, Cronos said revenue rose 58% year over year in its most recent quarter, following growth of 25% in 2025 and 35% in 2024. The company also reported record gross profit and gross margin in the latest quarter, citing GrowCo consolidation, international growth and greater exposure to higher-margin products such as vapes. Cronos said it has generated positive adjusted EBITDA for six consecutive quarters since the first quarter of 2025. The company reported CAD 827 million in cash and no debt, which Gorenstein said gives Cronos flexibility to pursue organic investment, acquisitions and share repurchases without relying on leverage or equity dilution. Gorenstein identified regulatory developments as the principal risk to the company's near-term growth trajectory. He said Cronos remains focused on growing faster than the Canadian market through pre-roll development, flower supply recovery and expansion in Israel and Europe. About Cronos Group (NASDAQ:CRON). Cronos Group Inc is a Toronto-based cannabinoid company that develops, produces, and commercializes cannabis and cannabis-derived products. The company serves both the adult-use and medical cannabis markets, with activities spanning cultivation, product development, manufacturing, and brand marketing. Cronos offers cannabis flower, pre-rolls, vaporizers, edibles, extracts, and other cannabis formats through brands including Spinach, PEACE NATURALS, and Lord Jones. Its products are distributed primarily through regulated cannabis channels, including provincial retail systems and medical or international markets where permitted by local laws. Founded in 2013, Cronos has expanded through brand development, product innovation, and strategic partnerships.

StratCann
Sep 1st, 2026
Cannabis jobs update - September 2026.

Cannabis jobs update - September 2026. September 1, 2026 Staff Canada's cannabis industry is hiring. In its September 2026 job roundup, StratCann Services Inc. has highlighted open roles in retail, cultivation, processing, brand management, and operational support. Whether you are an industry veteran looking for your next career move or a newcomer eager to enter the space, there are options available across every stage of the supply chain. Explore the listings below to find your fit. British columbia. The BCLDB is hiring a Store Manager, Cannabis Operations in Quesnel and a Supervisor, Cannabis Operations in the Lower Mainland. Both have a closing date of September 17, 2026. Prince Rupert Cannabis is hiring a part-time Budtender, in, you guessed it, Prince Rupert. The Pantheon Cannabis Group Inc. is seeking a Packaging Associate in Salmon Arm. Organnicraft has an open position for a Cannabis Trimmer in Vernon. Alberta. Spiritleaf is looking to hire a Cannabis Concierge for part-time evenings and weekends in Cold Lake. Saskatchewan. 5Buds Cannabis is hiring a Part-Time Supervisor in Yorkton, Warman, and Weyburn. Canna Cabana has several retail positions available across Saskatchewan. Ontario. Curaleaf International is hiring a Manufacturing Lead in Brampton. Cronos is hiring for positions in Finance, Marketing, Operations, Procurement, QAQC, and R&D in Stayner and Kingsville. HighLife Cannabis is seeking a Retail Store Manager in Smiths Falls. Canopy Growth is hiring for several positions across Ontario. Quebec. Cultures Chloris est à la recherche d'un Journalier/Journalière - Production de cannabis à Saint-Bernard. 9454-1901 Québec Inc. (doing business as WeedaFarm) is hiring a Cannabis Processor in Saint-Elphège. New brunswick. Newfoundland and labrador. The Herbal Centre is hiring a Budtender in St. John's. Nova scotia. Pei. Yukon. The Herbary is hiring Herbmasters in Whitehorse.

Yahoo Finance
Aug 31st, 2026
Cronos Group among 3 profitable penny stocks with stronger balance sheets

Global bond markets are pricing in higher policy rates as inflation persists, pushing investors towards penny stocks where balance sheet strength matters. A screener of financially fit penny stocks — companies trading under $5 per share — has identified 333 firms with stronger fundamentals. Cronos Group stands out in the cannabis sector. The company generates approximately $179 million in revenue from cannabis products across Canada, Israel, and international markets. Recent quarters delivered record net revenue, gross profit, and adjusted EBITDA, whilst brands like Spinach gained market share. The company maintains a strong balance sheet with significant cash reserves and ongoing share buybacks. However, reliance on external funding and expectations for weaker earnings over coming years present notable risks. For investors seeking profitable smaller cannabis companies rather than pure growth plays, Cronos offers a balanced mix of promise and caution worth closer examination.

Highly Capitalized
Aug 18th, 2026
Earnings season: cannabis operators deliver a different kind of Q2 2026.

Earnings season: cannabis operators deliver a different kind of Q2 2026. LOS ANGELES - The Cannabis industry wraps up its second-quarter earnings, and the aggregate picture carries a theme that would have been harder to locate a few years ago. Operators are making money. Profitability, not revenue scale, is the number that commands attention now. Cannamonitor Decide has compiled every result released through mid-August, spanning operators from Tallahassee to Tel Aviv. US msos: margins win the quarter. Among American multi-state Cannabis operators, the Q2 earnings season showed a sector holding profitability together even as top-line growth slowed. Curaleaf reported US$340 million in net revenue, up 10% year-over-year, with a 50% gross margin and US$70 million in adjusted EBITDA at a 21% margin. Green Thumb Industries posted US$307 million [approx. 5% growth] with US$84 million in normalized EBITDA at a 28% margin, though same-store sales fell 1%, partly reflecting industry-wide pricing pressure. Verano Holdings recorded US$218 million in revenue, up 8% year-over-year, while adjusted EBITDA declined to US$51 million from the prior-year period. The company completed a 1-for-5 reverse stock split during the quarter, a preparatory step toward a prospective U.S. exchange listing. Vireo Growth reported revenue of US$209.3 million for the quarter, up 335% year-over-year from $48.1 million in Q2 2025, driven by closed acquisitions. Trulieve, the first U.S. plant-touching Cannabis operator to list on the NYSE, had the most structurally layered quarter of the group. Revenue declined 10% to US$271 million, primarily reflecting the June deconsolidation of its adult-use Harvest operations, yet adjusted EBITDA reached US$98 million at a 36% margin, the highest result in the US peer set. The Curaleaf-Aurora bid. Curaleaf's Q2 results were quickly overtaken by a separate announcement. On August 11, the company publicly disclosed an unsolicited takeover bid for Aurora Cannabis, offering US$4.00 per share, a 45% premium to Aurora's 30-day volume-weighted average price, for a total consideration of approx. US$272 million. A combined entity, Curaleaf said, would operate across 17 countries with trailing 12-month revenue exceeding US$1.5 billion and pro-forma adjusted EBITDA approaching US$350 million. The company projects at least US$40 million in annual cost savings through supply chain integration, citing Aurora's 50-plus tons of annual EU-GMP cultivation capacity as the primary supply-side rationale. Curaleaf chairman and CEO Boris Jordan had initiated contact with Aurora's leadership in late June. Aurora declined to engage. By now, no formal negotiations had begun. Canadian producers pull ahead. The performance gap between US and Canadian operators was wider than many observers expected. Cronos Group reported a 58% year-over-year increase to C$53 million in net revenue; its tenth consecutive record quarter in Israel, driven by PEACE NATURALS flower demand in the Israeli medical market and Germany. Gross margin reached 54%, and the company swung to net income of US$35.7 million from a US$38.5 million net loss in the same period last year. Organigram grew revenue 49% [contribution from the April acquisition of Germany's Sanity Group], Rubicon Organics posted a record quarter, Auxly added 18%, and Canopy contributed 13% growth. International medical exposure and lighter excise structures are creating a differential the US domestic market cannot currently match. Europe's two-track quarter. Cantourage Group SE traded revenue scale for earnings quality. Q2 net revenue fell 22% year-over-year to €21.8 million, while EBITDA rose 45% to €2.9 million, lifting the EBITDA margin to 13.1%. UK and Poland drove the profitability gain. Poland's Cosma S.A. returned to profit, reporting PLN 7.3 million in revenue. Synbiotic SE went the other direction. Two CBD-facing subsidiaries [Solidmind, operator of the Hempamed brand, and Lean Labs Pharma] filed for insolvency in late July in Münster, sending Synbiotic shares down roughly 30%. CEO Daniel Kruse attributed the filings to a sharp demand contraction for CBD and hemp products starting in March 2026, compounded by ongoing regulatory ambiguity in that segment. The episode reinforces a distinction hardening across Europe. Medical-regulated Cannabis and consumer CBD are separate commercial businesses, with materially different capital and risk profiles. HCN insight. The Q2 results, read together, describe a market that has stopped reaching for revenue scale and started concentrating on cash. US operators are generating real margin on flat or declining revenue - a posture that reflects both market maturation and the pricing pressure that has persisted across state markets for several years. Canadian producers' international medical exposure, particularly in Germany and Israel, is delivering a growth rate the US domestic market cannot currently replicate, and the structural advantages of operating outside excise-heavy Canadian frameworks are clearly showing up in gross margins. The Curaleaf-Aurora bid, if it proceeds to close, would constitute one of the most notable cross-border transactions in Cannabis industry history, testing the premise that supply-chain consolidation across different regulatory jurisdictions can generate sufficient returns to justify the acquisition premium. In Europe, the divergence between medical-focused operators building toward sustained profitability and CBD-adjacent businesses absorbing unresolved regulatory uncertainty is no longer marginal. It is a defining split in how the region's Cannabis economy is taking shape. Capital moving through this sector has more quantitative clarity available today than at any prior point in its development. The Q2 2026 scoreboard gives it good reason to use that clarity carefully. The News Team at Highly Capitalized are some of the most experienced writers in cannabis and psychedelics business & finance. Highly Capitalized cover capital markets, finance, branding, marketing and everything important in between. Most of all, Highly Capitalized follow the money.